Video Series

VESALIUS-CV shows that evolocumab delivers a 31% relative risk reduction in major cardiovascular events in high-risk diabetic patients without established atherosclerosis—making a compelling case for intensive LDL lowering well before a first event.

Beyond standard risk scores, the guideline highlights key risk enhancers—including lipoprotein(a), inflammation markers, and women's health factors—and elevates coronary artery calcium scoring as a Class I tool for resolving uncertainty in primary prevention.

Long-acting CAB+RPV may maintain efficacy even with delayed injections, offering real-world flexibility.

For the first time, the 2026 ACC/AHA guideline provides strong, evidence-based recommendations for patients who cannot tolerate statins—a group historically underserved by prior guidance. Outcome data now support bempedoic acid (from the CLEAR trial), PCSK9 monoclonal antibodies, ezetimibe, and inclisiran as viable alternatives. Rather than defaulting to high-intensity statin doses, clinicians can consider combination strategies such as a moderate-intensity statin paired with ezetimibe—a pairing shown in the RACING trial to match the cardiovascular event reduction of high-intensity monotherapy while improving tolerability and LDL goal achievement. The "rule of sixes"—where doubling a statin dose yields only an additional 6% LDL reduction versus 18% from adding ezetimibe—further reinforces early combination thinking.

The 2026 update to the ACC/AHA guideline for dyslipidemia management represents a meaningful shift in how and when clinicians should begin lipid-lowering therapy, Erin D. Michos, MD, MHS, professor of medicine, director of Women's Cardiovascular Health and associate director of Preventive Cardiology in the Division of Cardiology at Johns Hopkins University School of Medicine, explains.

Chemotherapy sequencing in the ARPI era and the role of radiopharmaceuticals versus docetaxel remain unsettled, while genetics and PSMA-PET emerge as essential themes for community oncologists.

Benjamin Lockshin, MD, FAAD, offers a forward-looking synthesis of how psoriasis care has evolved toward holistic, personalized management—and where advances in oral therapies, biomarker-guided selection, and equitable access will define the next era of treatment.

Real-world data suggest long-acting injectables may help achieve—not just maintain—viral suppression.

Radium-223 retains a role in osteoblastic bone-only disease, while PSMA PET has become indispensable across staging, recurrence detection, and patient selection for radioligand therapy.

Benjamin Lockshin, MD, FAAD, examines the non-clinical reasons driving real-world treatment discontinuation and explains how clinicians use primary versus secondary loss of efficacy to guide biologic sequencing decisions across IL-23 and IL-17 classes.

Benjamin Lockshin, MD, FAAD, reviews real-world persistence data for tildrakizumab, discussing the interplay of clinical efficacy, insurance coverage, and buy-and-bill reimbursement in driving long-term treatment durability—particularly among Medicare and Medicaid patients.

DOR/ISL exemplifies how 2-drug regimens could meet the complex needs of an aging HIV population.

The mCRPC section's reorganization by prior treatment exposure reflects how ARPI and docetaxel use in the hormone-sensitive setting now defines—and constrains—options in the castration-resistant phase.

Benjamin Lockshin, MD, FAAD, examines how geographic variation in psoriasis patient characteristics and biologic prescribing reflects a complex interplay of insurance access, formulary structure, practice site demographics, and regional socioeconomic factors.

Benjamin Lockshin, MD, FAAD, outlines the clinical and practical factors driving the dominance of IL-23 inhibitors in biologic initiation, highlighting their favorable safety profile, ease of patient counseling, and versatility in managing psoriatic comorbidities.

Two-year data confirm DOR/ISL delivers durable viral suppression—even in patients with high viral loads or advanced disease.

Collapsing the very-low-risk category reflects broader acceptance of active surveillance for Gleason 6 disease, while PARP inhibitor eligibility now requires genetic testing at the hormone-sensitive stage.

Nonsteroidal topicals like roflumilast are enabling proactive, long-term psoriasis control across a broad range of patients, reducing reliance on corticosteroids and minimizing the need for systemic escalation.

Phase 3 data show DOR/ISL matches standard INSTI-based therapy in efficacy and safety, signaling a potential shift in first-line HIV treatment.

Real-world evidence complements clinical trial data by capturing how psoriasis therapies perform across diverse patient populations and treatment contexts in everyday practice.

New FDA approvals and emerging trial data drive two pivotal 2026 NCCN guideline updates: lutetium-177 PSMA-617 for taxane-naive mCRPC and PARP inhibitors in the hormone-sensitive setting.

How payers curb inappropriate ATTR-CM therapy use with better scans, prior auth, real-world outcomes, and telemedicine to speed access.

Experts weigh prior authorization, step therapy, and 12‑month coverage to balance access and cost for high‑value long‑term therapies.

Subcutaneous cancer therapy cuts chair time and IV needs, but brings site reactions, volume limits, and policy hurdles clinics must solve.

Real-world evidence and claims data compare amyloidosis therapies, linking outcomes and symptom burden to total cost of care.

In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists explore the key clinical and economic considerations that drive therapy selection across the three available ATTR-CM treatments. Dr. Alexander opens by emphasizing shared decision-making as a foundational principle, noting that in the absence of head-to-head data, patient preferences carry significant weight alongside clinical judgment. He outlines several practical factors influencing treatment choice, including route of administration, as vutrisiran is a quarterly injection given in a healthcare setting, acoramidis is a twice-daily oral pill, and tafamidis is a once-daily oral pill, each presenting distinct advantages depending on patient circumstances such as pill burden or transportation access.

Subcutaneous cancer therapy trims chair time and costs, but volume limits and reactions matter—learn how clinics streamline workflows.

Experts decode NSCLC PD‑L1 trials, when immunotherapy alone works, why crossover matters, and who still benefits from adding chemotherapy.